Microvascular Dysfunction in Obesity-Hypertension.

IF 3.9 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Current Hypertension Reports Pub Date : 2023-12-01 Epub Date: 2023-10-14 DOI:10.1007/s11906-023-01272-2

Tammy Do, Ashley Van, Arash Ataei, Swati Sharma, Rajesh Mohandas

{"title":"Microvascular Dysfunction in Obesity-Hypertension.","authors":"Tammy Do, Ashley Van, Arash Ataei, Swati Sharma, Rajesh Mohandas","doi":"10.1007/s11906-023-01272-2","DOIUrl":null,"url":null,"abstract":"Purpose of review: This review aims to explore the role of microvascular dysfunction in obesity-hypertension, discuss the effects obesity has on renal microvasculature, review the current methods for assessing microvascular dysfunction and available therapeutic options, and identify critical areas for further research.Recent findings: There is a strong association between obesity and hypertension. However, the pathophysiology of obesity-hypertension is not clear. Microvascular dysfunction has been linked to hypertension and obesity and could be an important mediator of obesity-related hypertension. Newer therapies for hypertension and obesity could have ameliorating effects on microvascular dysfunction, including GLP-1 agonists and SGLT-2 inhibitors. There is still much progress to be made in our understanding of the complex interplay between obesity, hypertension, and microvascular dysfunction. Continued efforts to understand microvascular dysfunction and its role in obesity-hypertension are crucial to develop precision therapy to target obesity-hypertension.","PeriodicalId":10963,"journal":{"name":"Current Hypertension Reports","volume":null,"pages":null},"PeriodicalIF":3.9000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Hypertension Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11906-023-01272-2","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/14 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: This review aims to explore the role of microvascular dysfunction in obesity-hypertension, discuss the effects obesity has on renal microvasculature, review the current methods for assessing microvascular dysfunction and available therapeutic options, and identify critical areas for further research.

Recent findings: There is a strong association between obesity and hypertension. However, the pathophysiology of obesity-hypertension is not clear. Microvascular dysfunction has been linked to hypertension and obesity and could be an important mediator of obesity-related hypertension. Newer therapies for hypertension and obesity could have ameliorating effects on microvascular dysfunction, including GLP-1 agonists and SGLT-2 inhibitors. There is still much progress to be made in our understanding of the complex interplay between obesity, hypertension, and microvascular dysfunction. Continued efforts to understand microvascular dysfunction and its role in obesity-hypertension are crucial to develop precision therapy to target obesity-hypertension.

Abstract Image

查看原文本刊更多论文

肥胖高血压患者的微血管功能障碍。

综述目的：本综述旨在探讨微血管功能障碍在肥胖-高血压中的作用，讨论肥胖对肾脏微血管的影响，综述目前评估微血管功能障碍的方法和可用的治疗方案，并确定进一步研究的关键领域。最近的研究结果：肥胖和高血压之间有很强的相关性。然而，肥胖高血压的病理生理学尚不清楚。微血管功能障碍与高血压和肥胖有关，可能是肥胖相关高血压的重要介质。针对高血压和肥胖的新疗法可能对微血管功能障碍有改善作用，包括GLP-1激动剂和SGLT-2抑制剂。在理解肥胖、高血压和微血管功能障碍之间的复杂相互作用方面，仍有许多进展。继续努力了解微血管功能障碍及其在肥胖性高血压中的作用，对于开发针对肥胖性高血压的精确治疗至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Hypertension Reports 医学-外周血管病

CiteScore

10.50

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of hypertension. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as antihypertensive therapies, associated metabolic disorders, and therapeutic trials. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.